What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Dr_Jamie_Murphy

Home
United Kingdom
London
Dr_Jamie_Murphy

Specalist cancer surgeon in London with clinical & research interest in advanced colorectal and peritoneal cancers

20/12/2025

🧬💉 Can a simple blood test help guide cancer treatment?

New research shows that ctDNA testing after surgery 🏥 for stage 3 (involved lymph nodes) may help identify who benefits from adding celecoxib 💊 (a non steroidal anti inflammatory drug used as pain killer) to chemotherapy — with up to a ⬇️ 40% reduction in cancer recurrence and death 📉 for patients who are ctDNA-positive after surgery.

This is precision medicine in action 🎯 — moving away from one-size-fits-all care and toward smarter, personalized treatment 🧠✨.

Not every patient benefits ❌ — but the right patient might ✅.

👉 Save 💾 if you follow cancer research
👉 Share 🔁 to spread awareness
💬 Comment 💭: Should ctDNA testing become standard after surgery?

21/10/2025

🆕 hope for advanced bowel cancer ✨

The recently published STELLAR-303 trial has brought some 🌟 encouraging news 🌟 for people living with stage 4 (advanced) colorectal cancer.

This large international 📖 tested a 🆕 treatment combo — 🧬 Zanzalintinib (tyrosine kinase inhibitor) + Atezolizumab (immunotherapy) — against the standard drug 💊 Regorafenib, which is approved for use in 🇬🇧 NHS and is usually used when first, second and third line treatments have stopped working. It’s important to highlight that the patients included in this study would not normally be candidates for immunotherapy (pMMR, MSS). A total of 901 patients were recruited and randomly allocated to the 🆕 or standard treatment options.

💡 What did it find?
➡️ People given the 🆕 combination had a longer average overall survival than people receiving Regorafenib — 10.9 months vs 9.4 months.
➡️ Interestingly the benefit from the new treatment was considerably greater for patients without spread to the liver — 15·9 months vs 12·7 months.
➡️ Side-effects were similar to other treatments (😴 tiredness, 💨 diarrhoea, 💓 high blood pressure) but were manageable with 👍 medical support.

🔬 Why it matters:
This combination brings immunotherapy and targeted therapy together for the majority of patients (micro satellite stable) — showing real hope for patients who’ve already had several rounds of treatment. It’s another step towards giving people more and better options.

💙 If you’re living with stage 4 bowel cancer, this doesn’t change today’s standard treatment just yet — but it’s a sign of hope that this new therapy may be available in the future. Talk to your oncologist to see if similar clinical trials might be open near you.

🌍💪💙

06/10/2025

Great to see importance of young patients with being discussed at

05/10/2025

Great honour to have been elected as Fellow of American College of Surgeons in Chicago today

06/08/2025

The integration of AI into bowel cancer treatment provides a promising future where treatment is increasingly tailored, precise, and effective.

In a recent Cancer Research UK‑led study, an AI‑based CD3 Score test analysed the density of CD3 immune cells in stage II bowel cancer tissues and accurately stratified patients by risk of recurrence over 5 years.

This breakthrough provides a more precise tool for deciding whether adjuvant chemotherapy is needed, helping some patients safely avoid unnecessary treatment and its side effects. It’s a promising step towards personalising care for early-stage colorectal cancer patients.

Read more here and see how it may inform HIPEC‑related decision-making - https://drjamiemurphy.co.uk/news/how-ai-is-helping-with-bowel-cancer-treatment/

28/06/2025

🔥🔥🔥The STELLAR‑303 study 🔥🔥🔥is a Phase 3 clinical trial comparing a 🆕 drug combination —zanzalintinib (an experimental tyrosine kinase inhibitor) plus atezolizumab (an immunotherapy drug) — against regorafenib, a currently available standard treatment, for patients with metastatic (mCRC). STELLAR‑303 recruited approximately 900 adults with mismatch repair proficient (pMMR / MSS) mCRC, who had cancer progression after all standard options had been exhausted (5FU, capecitabine, irinotecan, oxaliplatin ± Avastin, cetuximab or panitumimab if RAS wild-type, and BRAF-targeted therapy if applicable). Exelixis, the company 🏃 this trial, announced this week that STELLAR‑303 met its primary endpoint, demonstrating a statistically significant improvement in overall survival. The 📈 have not yet been released from the trial and will be presented in the coming weeks. However, the hope is this is a step toward being able to offer to the c.85% of mCRC patients who aren’t currently eligible due to having mismatch repair proficient disease. Discussions are being had with the 🇺🇸 FDA so this is 1️⃣ to ⌚️ 🤞🤞🤞

03/06/2025

🔥 So 1️⃣ of the studies presented at ASCO 2025 many of you will have read about in the press is The Challenge trial 🔥 This randomised patients with high risk stage 2 or stage 3 who had completed after surgery to either have a structured exercise prescription (SEP) or to receive health educational materials (HEM). 445 patients were randomised to SEP and 444 patients were randomised to HEM. Most patients in the SEP group could hit their 🏃‍♂️ 🎯 by adding a 45-60 min brisk walk to their routine 3-4 ✖️ per week. Both overall survival and disease 🆓 survival were significantly improved in the SEP group, which seems to be predominantly due to a decrease in cancer recurrence in liver. The authors indicate that for every 14 people who participated in SEP 1️⃣ 🧍 was prevented from dying of cancer. Furthermore the risk of developing a second 🆕 cancer in the breast, prostate or colon was lower in the SEP group. The assessment of the authors or this 📖 is that the SEP may actually have a greater impact on survival than post surgery chemo! This is really exciting data and this represents a 🆕 standard of care for people with . However it does mean we will need lots more physiotherapists to deliver these SEP, but given the impact of this is something that must be done 🏃‍♀️💪🏋️‍♂️

31/05/2025

🚨 🆕 📖 update from ASCO 25! 🚨 This 📖 looked at a 🆕 combination of drugs (encorafenib plus cetuximab, with or without chemotherapy) to treat patients with stage 4 and a BRAF V600E mutation. A previous 📖 showed that adding these 🆕 drugs to standard chemotherapy worked better than standard treatment alone, so the 🇺🇸 FDA gave this 🆕 combination early approval. Researchers have now released updated results.

Adding encorafenib plus cetuximab to chemotherapy (FOLFOX) helped people live longer without their cancer getting worse compared to standard chemotherapy (average 12.8 months vs. 7.1 months). It also helped people live longer overall (average 30.3 months vs. 15.1 months). Serious side effects happened in about 46% of people taking the 🆕 drugs plus chemotherapy, compared to 39% with standard chemotherapy. The types of side effects seen were what would be expected for these treatments.

For people with mutated stage 4 , starting treatment with the 🆕 drug combination and chemotherapy helped them live longer and kept their cancer under control longer than compared to standard treatment!

🌟

24/05/2025

Results of long awaited CAIRO6 trial being reported at ASCO ! Congratulations to trial team for completing this absolutely critical study. While will need to wait for the presentation, the abstract suggests moving to the Dutch strategy of CRS HIPEC up front rather than systemic chemotherapy does not decrease overall survival. Look forward to seeing results so can understand - what proportion of patients didn’t receive adjuvant chemotherapy due to surgical complications, the outcome of patients with RAS / RAF mutations, and discussions regarding optimal management stragey for patients with MMR deficient disease.

26/04/2025

This week performed first Gastric PIPAC treatment in England as part of PICCOS study following our colleagues in Wales. Massive team effort. Thanks to all those who supported it & most importantly the patients who put their trust in the trial

13/04/2025

On 8 April the 🇺🇸 Food and Drug Administration (FDA) approved a 🆕 first line combination therapy for certain advanced colorectal cancers. This treatment pairs 2️⃣ immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), for that cannot be surgically removed or that has spread to other parts of the body.

Colorectal cancer can sometimes have genetic features called “MSI-H” (microsatellite instability-high) also known as “dMMR” (deficient mismatch repair). These features make the cancer more responsive to immunotherapies. The newly approved combination therapy targets these specific cancer types, enhancing the body’s immune response to fight the cancer cells more effectively.

The FDA approval is based on results from the CheckMate 8HW clinical trial, which compared the 🆕 combination therapy to standard chemotherapy. The median progression-free survival (🕰️ during and after treatment where the disease does not grow) was not reached in the immunotherapy group, indicating 👍 disease control, as compared to an average of 5.8 months in the standard chemotherapy group.

The FDA approval not only provides a 🆕 treatment option for patients with MSI-H or dMMR colorectal cancer but it also signifies a shift towards more personalised cancer therapies. For patients and families affected by this type of colorectal cancer, this development offers renewed hope and underscores the importance of genetic testing in guiding cancer treatment decisions.

12/01/2025

off press! 4️⃣ days ago the 🇺🇸 Food and Drug Administration granted fast track designation to a 🆕 treatment strategy for . Invikafusp alfa has been shown to activate very specific parts of the immune system (Vβ6/Vβ10 TCR-expressing CD8+ and CD4+ effector memory T cells). These particular immune cells have been shown in 🔬 studies to be able to kill tumour cells designated as having high tumour mutational burden (TMB) that are resistant to immunotherapy. The phase 1/2 START002 📖 looked at Invikafusp alfa in 35 patients with an average of 4 different lines of chemotherapy treatment. Stable disease was reported in half (56%) of patients with 8 patients experiencing tumor shrinkage, including 2 ✅ partial responses. Now I should highlight 2️⃣ things - 1) this is only for people with TMB high cancer (similar to but not same as MSI / dMMR) which is not something routinely checked in 🇬🇧; and 2.) that despite FDA approval of Invikafusp alfa these are very early 📈. An 🇺🇸 Phase 2 clinical trial of Invikafusp alfa is underway. If these 📈 are ✅ we could be 👀 at a 🆕 class of treatment for tumor types that are insensitive or resistant to immunotherapy.🤞🤞🤞

Address

24 Portland Place
London
W1B1LU

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+442034237500

Website

https://clevelandcliniclondon.uk/doctors/744-prof-jamie-murphy

Alerts

Be the first to know and let us send you an email when Dr_Jamie_Murphy posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Dr_Jamie_Murphy:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Featured

Help Mind Body

Want your practice to be the top-listed Clinic in London?